Biocept Announces Validation and Availability of its Liquid Biopsy Platform for the Detection of Actionable Cancer Biomarkers in Cerebrospinal Fluid
"Testing the CSF for cancer biomarkers in patients suspected to have brain metastases can be important, as the rapid confirmation and characterization of CNS involvement enables appropriate treatment selection in a timely manner," stated
"We are very pleased to make our Target Selector™ platform available for testing CSF, as a more rapid identification of molecular alterations in brain metastases can aid physicians in choosing the best treatment options for their patients with breast or lung cancer," said
About CSF Testing
A medical procedure known as a spinal tap or lumbar puncture is typically done to collect CSF when cancer patients present with CNS symptoms, for example confusion or dementia. Over 200,000 of these procedures are performed annually in the U.S.
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer and the potential clinical utility of our proprietary technology platform as applied to CSF, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Contacts
Investors:
LHA Investor Relations
Jcain@lhai.com
310-691-7100
Media:
CORE IR
julesa@coreir.com
917-885-7378
View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-announces-validation-and-availability-of-its-liquid-biopsy-platform-for-the-detection-of-actionable-cancer-biomarkers-in-cerebrospinal-fluid-300985044.html
SOURCE